Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis
Completed · Phase 2 · Has a placebo group
Conditions studied: Seasonal Allergic Rhinitis
In brief
This is a clinical study to evaluate the safety and efficacy of a bepotastine besilate-corticosteroid combination nasal spray for the treatment of seasonal allergic rhinitis (SAR) in an open exposure study with subjects who have a demonstrated history of Mountain Cedar pollen allergy. The primary study objective is to assess the reduction from baseline in averaged morning (AM) and evening (PM) values of reflective total nasal symptom scores for each of 3 nasal sprays (bepotastine besilate-fluticasone propionate combination nasal spray, bepotastine besilate nasal spray, fluticasone propionate nasal spray) compared to placebo nasal spray. For enrolled subjects, the study will involve a 7-10 day run-in screening period dosing with placebo nasal spray and then a 14-day treatment period where subjects will dose twice a day with 1 of the 4 test agent nasal sprays and record reflective and instantaneous scores for both nasal and ocular symptoms prior to each dosing.
Key facts
- Study ID
- NCT01578278
- Run by
- Bausch & Lomb Incorporated
- People needed
- 606
- Starts
- 2011-12-01
- Expected to finish
- 2012-08-01
- Last updated by the study team
- 2020-10-05
Who can join
Age: 12 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male or female at least 12 years of age with a demonstrated history of Mountain Cedar pollen allergy
You may not qualify if…
- No active nasal infection or nasal abnormality that would affect subject safety or symptom assessments
Where it is running
- ISTA Pharmaceuticals, Inc. — Irvine, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.